Faron Pharmaceuticals Oy (LON:FARN) Sets New 52-Week Low – Should You Sell?

Shares of Faron Pharmaceuticals Oy (LON:FARN) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 38 and last traded at GBX 44.40, with a volume of 162288 shares. The stock had previously closed at GBX 45.40.

Faron Pharmaceuticals Oy Trading Down 2.2%

The company has a market capitalization of £55.90 million, a P/E ratio of -2.01 and a beta of 1.18. The stock’s 50 day moving average is GBX 61.38 and its 200-day moving average is GBX 139.21. The company has a debt-to-equity ratio of -133.35, a current ratio of 0.84 and a quick ratio of 1.09.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.